Enwei Pharmaceutical Co (SZSE:301331) Piotroski F-Score: 5 (As of Aug. 28, 2026) — Near Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SZSE:301331 Enwei Pharmaceutical Co Ltd SZSE:301331
76 GF Score
Price ¥21.84
GF Value ¥28.16
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Enwei Pharmaceutical Co Piotroski F-Score?

Enwei Pharmaceutical Co SZSE:301331 -0.86% 76 Piotroski F-Score is 5 as of Aug. 28, 2026, which is at its 10-year median of 5.00. GuruFocus rates SZSE:301331 with a GF Score™ of 76/100 and a GF Value™ of ¥28.16 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 985 Drug Manufacturers companies, Enwei Pharmaceutical Co ranks better than 61.02% on this metric.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Enwei Pharmaceutical Co has an F-score of 5 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Enwei Pharmaceutical Co's Piotroski F-Score or its related term are showing as below:

SZSE:301331' s Piotroski F-Score Range Over the Past 10 Years
Min: 4   Med: 5   Max: 8
Current: 5

During the past 9 years, the highest Piotroski F-Score of Enwei Pharmaceutical Co was 8. The lowest was 4. And the median was 5.

Enwei Pharmaceutical Co  (SZSE:301331) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Enwei Pharmaceutical Co Piotroski F-Score Related Terms


Enwei Pharmaceutical Co Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Enwei Pharmaceutical Co's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enwei Pharmaceutical Co Piotroski F-Score Chart

Enwei Pharmaceutical Co Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only 7.00 4.00 4.00 6.00 5.00

Enwei Pharmaceutical Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.00 7.00 7.00 5.00 5.00

SZSE:301331 vs ZTS: Piotroski F-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Enwei Pharmaceutical Co's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Enwei Pharmaceutical Co Piotroski F-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Enwei Pharmaceutical Co's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Enwei Pharmaceutical Co's Piotroski F-Score falls into.


SZSE:301331
76GF Score
Enwei Pharmaceutical Co Ltd SZSE:301331
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Net Income was 22.039 + -1.76 + 15.36 + 12.505 = ¥48.1 Mil.
Cash Flow from Operations was 50.504 + 1.02 + 33.391 + -3.492 = ¥81.4 Mil.
Revenue was 252.722 + 187.632 + 263.918 + 175.329 = ¥879.6 Mil.
Gross Profit was 125.985 + 86.557 + 138.88 + 97.64 = ¥449.1 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was
(1496.27 + 1515.985 + 1496.709 + 1550.663 + 1498.885) / 5 = ¥1511.7024 Mil.
Total Assets at the begining of this year (Mar25) was ¥1,496.3 Mil.
Long-Term Debt & Capital Lease Obligation was ¥0.9 Mil.
Total Current Assets was ¥920.0 Mil.
Total Current Liabilities was ¥390.3 Mil.
Net Income was 9.511 + 4.088 + 15.476 + 16.305 = ¥45.4 Mil.

Revenue was 204.674 + 172.192 + 251.786 + 196.499 = ¥825.2 Mil.
Gross Profit was 109.136 + 84.152 + 127.179 + 94.571 = ¥415.0 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was
(1355.537 + 1471.326 + 1422.895 + 1504.529 + 1496.27) / 5 = ¥1450.1114 Mil.
Total Assets at the begining of last year (Mar24) was ¥1,355.5 Mil.
Long-Term Debt & Capital Lease Obligation was ¥186.4 Mil.
Total Current Assets was ¥942.0 Mil.
Total Current Liabilities was ¥212.5 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Enwei Pharmaceutical Co's current Net Income (TTM) was 48.1. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Enwei Pharmaceutical Co's current Cash Flow from Operations (TTM) was 81.4. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar25)
=48.144/1496.27
=0.03217601

ROA (Last Year)=Net Income/Total Assets (Mar24)
=45.38/1355.537
=0.03347751

Enwei Pharmaceutical Co's return on assets of this year was 0.03217601. Enwei Pharmaceutical Co's return on assets of last year was 0.03347751. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Enwei Pharmaceutical Co's current Net Income (TTM) was 48.1. Enwei Pharmaceutical Co's current Cash Flow from Operations (TTM) was 81.4. ==> 81.4 > 48.1 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar25 to Mar26
=0.934/1511.7024
=0.00061785

Gearing (Last Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=186.376/1450.1114
=0.1285253

Enwei Pharmaceutical Co's gearing of this year was 0.00061785. Enwei Pharmaceutical Co's gearing of last year was 0.1285253. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar26)=Total Current Assets/Total Current Liabilities
=920.021/390.258
=2.35746865

Current Ratio (Last Year: Mar25)=Total Current Assets/Total Current Liabilities
=942.026/212.532
=4.43239606

Enwei Pharmaceutical Co's current ratio of this year was 2.35746865. Enwei Pharmaceutical Co's current ratio of last year was 4.43239606. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Enwei Pharmaceutical Co's number of shares in issue this year was 103.174. Enwei Pharmaceutical Co's number of shares in issue last year was 99.97. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=449.062/879.601
=0.51052921

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=415.038/825.151
=0.5029843

Enwei Pharmaceutical Co's gross margin of this year was 0.51052921. Enwei Pharmaceutical Co's gross margin of last year was 0.5029843. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar25)
=879.601/1496.27
=0.58786248

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar24)
=825.151/1355.537
=0.60872628

Enwei Pharmaceutical Co's asset turnover of this year was 0.58786248. Enwei Pharmaceutical Co's asset turnover of last year was 0.60872628. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+0+1+1+0+0+1+0
=5

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Enwei Pharmaceutical Co has an F-score of 5 indicating the company's financial situation is typical for a stable company.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 5 mean?
Enwei Pharmaceutical Co (SZSE:301331) has a Piotroski F-Score of 5 as of Aug. 28, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Enwei Pharmaceutical Co and its competitors. This is near median its historical median of 5.00. Over the past decade, Enwei Pharmaceutical Co's Piotroski F-Score has ranged from 4.00 to 8.00. According to the industry distribution chart, Enwei Pharmaceutical Co ranks #384 out of 985 companies in the Drug Manufacturers industry, placing it in the top 39%.
Is Enwei Pharmaceutical Co's Piotroski F-Score too high?
Enwei Pharmaceutical Co's current Piotroski F-Score of 5 is near median its 10-year median of 5.00. Over the past 10 years, this metric has ranged from a low of 4.00 to a high of 8.00. The Drug Manufacturers industry median Piotroski F-Score is 5.00. Enwei Pharmaceutical Co's value of 5 is 0% at this industry median. Based on the distribution chart, Enwei Pharmaceutical Co ranks #384 out of 985 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Enwei Pharmaceutical Co has a GF Score™ of 76/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Enwei Pharmaceutical Co's Piotroski F-Score compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Enwei Pharmaceutical Co ranks #384 out of 985 companies for Piotroski F-Score. This puts Enwei Pharmaceutical Co in the upper half of its industry. The industry median Piotroski F-Score is 5.00. Enwei Pharmaceutical Co's value of 5 is 0% at this benchmark. Historically, Enwei Pharmaceutical Co's own Piotroski F-Score has ranged from 4.00 to 8.00 over the past decade. While the company's 10-year median is 5.00 vs. the industry median of 5.00, Enwei Pharmaceutical Co has consistently been at the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Drug Manufacturers company?
The median Piotroski F-Score among Drug Manufacturers companies is 5.00, based on 985 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Enwei Pharmaceutical Co's current Piotroski F-Score of 5 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Enwei Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Enwei Pharmaceutical Co's current Piotroski F-Score is 5, which is near median its own 10-year median of 5.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Enwei Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Enwei Pharmaceutical Co (SZSE:301331) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥28.16, compared to a current price of ¥21.84 — trading 22.4% below its estimated fair value. The current Piotroski F-Score is 5, which is near median its 10-year median of 5.00 and 0% at the Drug Manufacturers industry median of 5.00. Enwei Pharmaceutical Co's overall GF Score™ is 76/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Enwei Pharmaceutical Co (SZSE:301331), the current Piotroski F-Score is 5 as of Aug. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Enwei Pharmaceutical Co (SZSE:301331) Overvalued in 2026?

Based on GuruFocus' analysis, Enwei Pharmaceutical Co stock appears to be undervalued. The current stock price of ¥21.84 is trading 22.4% below its estimated GF Value™ of ¥28.16. GuruFocus considers Enwei Pharmaceutical Co to be Modestly Undervalued.

Key valuation signals for SZSE:301331:

  • Piotroski F-Score: 5 (near median its 10-year median of 5.00)
  • GF Value™: ¥28.16 vs. price of ¥21.84 (22.4% below fair value)
  • GF Score™: 76/100 with 4 warning signs
  • Industry Position: 0% at the Drug Manufacturers median (#384 of 985)

No single metric tells the full story. See the SZSE:301331 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Enwei Pharmaceutical Co Business Description

Address No. 458, Section 3, Shuanghua Road, Shuangliu District, Chengdu, Sichuan Province, Changdu, CHN, 610200
Enwei Pharmaceutical Co Ltd is engaged in the research and development, production, and sales of proprietary Chinese medicines and chemical medicines. The company mainly procures Chinese medicinal herbs, processed Chinese medicinal herbs, chemical raw materials, excipients, packaging materials, plastics, and other miscellaneous items.
76GF Score

Get the complete analysis for SZSE:301331

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥21.84
Price
¥28.16
GF Value